KRAS and myeloid neoplasm: Our observations of RAS pathway co-alterations (CBL and KRAS) in the EPI6 signature aligns with the documented activation of this pathway in CUX1-altered MNs, as recently demonstrated in the context of 7q alterations in myeloid neoplasms [33].